SEC Filing Summary: Form 13F-HR
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Sarepta Therapeutics, Inc., an institutional investment manager, for the quarter ended March 31, 2026. The report was signed by Ryan Wong, Executive Vice President and Chief Financial Officer, on May 13, 2026.
Key Financial Metrics
As a Form 13F filing, this document reports securities holdings rather than the company's operational financial performance. Consequently, the filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for Sarepta Therapeutics, Inc. itself.
- Total Value of Reported Holdings: $0
- Number of Holdings Reported: 1
- Other Included Managers: 0
Material Changes
The filing indicates a total value of $0 for the reported holdings. The text does not provide comparative data from prior periods to determine material changes in the portfolio value or composition.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly discloses the securities held by the reporting manager at the end of the quarter.
Investor Verification Checklist
- Verify the discrepancy between the filer name (Sarepta Therapeutics, Inc.) and the nature of the report (13F Holdings), as Sarepta is typically a biopharmaceutical operating company rather than an investment manager.
- Confirm the accuracy of the reported total value of $0, which suggests no reportable equity holdings were held by this entity at the reporting date.
- Review the specific security listed in the "1" entry of the Information Table to understand the nature of the holding.
- Check for any subsequent amendments or restatements filed after May 13, 2026.